CAL-101 (BioDeep_00000715665)
代谢物信息卡片
Idelalisib
化学式: C22H18FN7O (415.15567899999996)
中文名称: 艾代拉利司
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
InChI: InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EM - Phosphatidylinositol-3-kinase (pi3k) inhibitors
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor
D000970 - Antineoplastic Agents
D004791 - Enzyme Inhibitors
同义名列表
2 个代谢物同义名
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:82701
- KEGGdrug: D10560
- PubChem: 11625818
- DrugBank: DB09054
- ChEMBL: CHEMBL2216870
- CAS: 1146702-54-6
- CAS: 1453810-72-4
- CAS: 870281-82-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Anup Siddesh, Dhurvu Sriram, Ashok Zakkula, Rajnish Kumar, Sreekanth Dittakavi, Mohd Zainuddin, Ravi Kumar Trivedi, Ramesh Mullangi. Validated HPLC-UV method for simultaneous quantification of phosphatidylinositol 3-kinase inhibitors, copanlisib, duvelisib and idelalisib, in rat plasma: Application to a pharmacokinetic study in rats.
Biomedical chromatography : BMC.
2021 Apr; 35(4):e5015. doi:
10.1002/bmc.5015. [PMID: 33125719] - Noriko Fukuhara, Tomohiro Kinoshita, Kazuhito Yamamoto, Hirokazu Nagai, Koji Izutsu, Go Yamamoto, Pankaj Bhargava, Nishan Rajakumaraswamy, Rita Humeniuk, Anita Mathias, Guan Xing, Masato Fukui, Kensei Tobinai. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
Japanese journal of clinical oncology.
2020 Dec; 50(12):1395-1402. doi:
10.1093/jjco/hyaa153. [PMID: 32856068] - Eric P Allain, Michèle Rouleau, Katrina Vanura, Sophie Tremblay, Joanie Vaillancourt, Vincent Bat, Patrick Caron, Lyne Villeneuve, Adrien Labriet, Véronique Turcotte, Trang Le, Medhat Shehata, Susanne Schnabl, Dita Demirtas, Rainer Hubmann, Charles Joly-Beauparlant, Arnaud Droit, Ulrich Jäger, Philipp B Staber, Eric Lévesque, Chantal Guillemette. UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
British journal of cancer.
2020 07; 123(2):240-251. doi:
10.1038/s41416-020-0887-6. [PMID: 32418995] - Tianyi Xin, Haote Han, Wenyi Wu, Xionggao Huang, Jing Cui, Joanne Aiko Matsubara, Jingyuan Song, Fang Wang, Marcus Colyer, Hetian Lei. Idelalisib inhibits vitreous-induced Akt activation and proliferation of retinal pigment epithelial cells from epiretinal membranes.
Experimental eye research.
2020 01; 190(?):107884. doi:
10.1016/j.exer.2019.107884. [PMID: 31786159] - Giulia Gabrielli, Alessandro Broccoli, Cinzia Pellegrini, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani. Idelalisib as a Bridge to Allogeneic Transplantation in Relapsed/Refractory Lymphoma With Renal Cancer: A Case Report.
Clinical lymphoma, myeloma & leukemia.
2020 01; 20(1):e15-e17. doi:
10.1016/j.clml.2019.10.008. [PMID: 31711891] - Giuseppe Palma, Teresa Pasqua, Giovannino Silvestri, Carmine Rocca, Paola Gualtieri, Antonio Barbieri, Anna De Bartolo, Antonino De Lorenzo, Tommaso Angelone, Ennio Avolio, Gerardo Botti. PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19.
Frontiers in immunology.
2020; 11(?):2094. doi:
10.3389/fimmu.2020.02094. [PMID: 32973818] - Merrie Mosedale, Yanwei Cai, John Scott Eaddy, Robert W Corty, Manisha Nautiyal, Paul B Watkins, William Valdar. Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach.
Toxicological sciences : an official journal of the Society of Toxicology.
2019 12; 172(2):265-278. doi:
10.1093/toxsci/kfz199. [PMID: 31501888] - Jacob D Soumerai, Ai Ni, Mohamed Darif, Anil Londhe, Guan Xing, Yong Mun, Neil E Kay, Tait D Shanafelt, Kari G Rabe, John C Byrd, Asher A Chanan-Khan, Richard R Furman, Peter Hillmen, Jeffrey Jones, John F Seymour, Jeffrey P Sharman, Lucille Ferrante, Mehrdad Mobasher, Thomas Stark, Vijay Reddy, Lyndah K Dreiling, Pankaj Bhargava, Angela Howes, Danelle F James, Andrew D Zelenetz. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
The Lancet. Haematology.
2019 Jul; 6(7):e366-e374. doi:
10.1016/s2352-3026(19)30085-7. [PMID: 31109827] - Shubham Srivastava, Bhanwar Singh Choudhary, Pakhuri Mehta, Sukanya, Manish Sharma, Ruchi Malik. Molecular dynamics insights for PI3K-δ inhibition & structure guided identification of novel PI3K-δ inhibitors.
Journal of biomolecular structure & dynamics.
2019 Jun; 37(9):2404-2414. doi:
10.1080/07391102.2018.1489304. [PMID: 30047836] - Xiaodong Ma, Jun Wei, Chang Wang, Dongyan Gu, Yongzhou Hu, Rong Sheng. Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies.
European journal of medicinal chemistry.
2019 May; 170(?):112-125. doi:
10.1016/j.ejmech.2019.03.005. [PMID: 30878826] - Cuiyun Wang, Fei Jia, Yafei Zhang. Simultaneous determination of idelalisib and its metabolite GS-563117 in dog plasma by LC-MS/MS: Application to a pharmacokinetic study.
Biomedical chromatography : BMC.
2019 May; 33(5):e4511. doi:
10.1002/bmc.4511. [PMID: 30773664] - JaeSang Ko, Ji-Young Kim, Eun Jig Lee, Jin Sook Yoon. Inhibitory Effect of Idelalisib, a Selective Phosphatidylinositol 3-Kinase δ Inhibitor, on Adipogenesis in an In Vitro Model of Graves' Orbitopathy.
Investigative ophthalmology & visual science.
2018 09; 59(11):4477-4485. doi:
10.1167/iovs.18-24509. [PMID: 30193323] - Junjie Zhu, Pengcheng Wang, Amina I Shehu, Jie Lu, Huichang Bi, Xiaochao Ma. Identification of Novel Pathways in Idelalisib Metabolism and Bioactivation.
Chemical research in toxicology.
2018 07; 31(7):548-555. doi:
10.1021/acs.chemrestox.8b00023. [PMID: 29896955] - M D'Aveni-Piney, M Divoux, H Busby-Venner, M Muller, J Broséus, P Feugier. Idelalisib in a patient with refractory Waldenström's macroglobulinemia complicated by anuric renal failure: a case report.
Journal of medical case reports.
2018 Jun; 12(1):164. doi:
10.1186/s13256-018-1694-z. [PMID: 29890999] - Chen-Chen Ma, Cheng-Mei Zhang, Long-Qian Tang, Zhao-Peng Liu. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
European journal of medicinal chemistry.
2018 May; 151(?):9-17. doi:
10.1016/j.ejmech.2018.03.068. [PMID: 29601991] - Huu H Huynh, Clara Roessle, Hélène Sauvageon, Alain Plé, Isabelle Madelaine, Catherine Thieblemont, Samia Mourah, Lauriane Goldwirt. Quantification of Idelalisib in Human Plasma by Ultra-Performance Liquid Chromatography Coupled to Mass Spectrometry in Negative Ionization Mode.
Therapeutic drug monitoring.
2018 04; 40(2):237-244. doi:
10.1097/ftd.0000000000000488. [PMID: 29529009] - Andrea Visentin, Chiara Briani, Silvia Imbergamo, Federica Frezzato, Annalisa Angelini, Marny Fedrigo, Mario Cacciavillani, Sara Altinier, Francesco Piazza, Gianpietro Semenzato, Fausto Adami, Livio Trentin. Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia.
Hematological oncology.
2018 Feb; 36(1):366-369. doi:
10.1002/hon.2480. [PMID: 28971495] - Shida Yang, Zhiyong Zhu, Xiaobing Zhang, Ning Zhang, Zhicheng Yao. Idelalisib induces PUMA-dependent apoptosis in colon cancer cells.
Oncotarget.
2017 Jan; 8(4):6102-6113. doi:
10.18632/oncotarget.14043. [PMID: 28008149] - Marco Falasca, Justin R Hamilton, Maria Selvadurai, Krithika Sundaram, Aleksandra Adamska, Philip E Thompson. Class II Phosphoinositide 3-Kinases as Novel Drug Targets.
Journal of medicinal chemistry.
2017 01; 60(1):47-65. doi:
10.1021/acs.jmedchem.6b00963. [PMID: 27644332] - Friedrich Horak, Kamal D Puri, Bart H Steiner, Leanne Holes, Guan Xing, Petra Zieglmayer, René Zieglmayer, Patrick Lemell, Albert Yu. Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis.
The Journal of allergy and clinical immunology.
2016 06; 137(6):1733-1741. doi:
10.1016/j.jaci.2015.12.1313. [PMID: 26915677] - Paul M Barr, Gene B Saylors, Stephen E Spurgeon, Bruce D Cheson, Daniel R Greenwald, Susan M O'Brien, Andre K D Liem, Rosemary E Mclntyre, Adarsh Joshi, Esteban Abella-Dominicis, Michael J Hawkins, Anita Reddy, Julie Di Paolo, Hank Lee, Joyce He, Jing Hu, Lyndah K Dreiling, Jonathan W Friedberg. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.
Blood.
2016 05; 127(20):2411-5. doi:
10.1182/blood-2015-12-683516. [PMID: 26968534] - Martin F M de Rooij, Annemieke Kuil, Willem Kraan, Marie José Kersten, Steven P Treon, Steven T Pals, Marcel Spaargaren. Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.
Haematologica.
2016 Mar; 101(3):e111-5. doi:
10.3324/haematol.2015.137265. [PMID: 26635033] - Srinivasan Ramanathan, Feng Jin, Shringi Sharma, Brian P Kearney. Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib.
Clinical pharmacokinetics.
2016 Jan; 55(1):33-45. doi:
10.1007/s40262-015-0304-0. [PMID: 26242379] - Feng Jin, Yuying Gao, Huafeng Zhou, Lorna Fang, Xiaoming Li, Srini Ramanathan. Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies.
Cancer chemotherapy and pharmacology.
2016 Jan; 77(1):89-98. doi:
10.1007/s00280-015-2891-8. [PMID: 26645408] - Solomon A Graf, Ajay K Gopal. Idelalisib for the treatment of non-Hodgkin lymphoma.
Expert opinion on pharmacotherapy.
2016; 17(2):265-74. doi:
10.1517/14656566.2016.1135130. [PMID: 26818003] - F Jin, M Robeson, H Zhou, G Hisoire, S Ramanathan. The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment.
Cancer chemotherapy and pharmacology.
2015 Dec; 76(6):1133-41. doi:
10.1007/s00280-015-2898-1. [PMID: 26526983] - Andrew Davies. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.
Expert review of hematology.
2015 Oct; 8(5):581-93. doi:
10.1586/17474086.2015.1071663. [PMID: 26343890] - Xiang Wang, Jian Ding, Ling-hua Meng. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
Acta pharmacologica Sinica.
2015 Oct; 36(10):1170-6. doi:
10.1038/aps.2015.71. [PMID: 26364801] - Feng Jin, Michelle Robeson, Huafeng Zhou, Grace Hisoire, Srini Ramanathan. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment.
Journal of clinical pharmacology.
2015 Aug; 55(8):944-52. doi:
10.1002/jcph.504. [PMID: 25821156] - Feng Jin, Michelle Robeson, Huafeng Zhou, Candra Moyer, Sibylle Wilbert, Bernard Murray, Srini Ramanathan. Clinical drug interaction profile of idelalisib in healthy subjects.
Journal of clinical pharmacology.
2015 Aug; 55(8):909-19. doi:
10.1002/jcph.495. [PMID: 25760671] - Jennifer R Brown, John C Byrd, Steven E Coutre, Don M Benson, Ian W Flinn, Nina D Wagner-Johnston, Stephen E Spurgeon, Brad S Kahl, Celeste Bello, Heather K Webb, Dave M Johnson, Sissy Peterman, Daniel Li, Thomas M Jahn, Brian J Lannutti, Roger G Ulrich, Albert S Yu, Langdon L Miller, Richard R Furman. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Blood.
2014 May; 123(22):3390-7. doi:
10.1182/blood-2013-11-535047. [PMID: 24615777] - Richard R Furman, Jeff P Sharman, Steven E Coutre, Bruce D Cheson, John M Pagel, Peter Hillmen, Jacqueline C Barrientos, Andrew D Zelenetz, Thomas J Kipps, Ian Flinn, Paolo Ghia, Herbert Eradat, Thomas Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R Pettitt, Shuo Ma, Stephan Stilgenbauer, Paula Cramer, Maria Aiello, Dave M Johnson, Langdon L Miller, Daniel Li, Thomas M Jahn, Roger D Dansey, Michael Hallek, Susan M O'Brien. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
The New England journal of medicine.
2014 Mar; 370(11):997-1007. doi:
10.1056/nejmoa1315226. [PMID: 24450857] - Sridhar Veeraraghavan, Satheeshmanikandan Thappali, Srikant Viswanadha, Santhoshkumar Nalla, Sandhyarani Chennupati, Manikantakumar Golla, Swaroopkumar Vakkalanka, Manivannan Rangasamy. Simultaneous quantification of idelalisib, fludarabine and lenalidomide in rat plasma by using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2014 Feb; 949-950(?):63-9. doi:
10.1016/j.jchromb.2014.01.001. [PMID: 24463402] - Jorge J Castillo, Michael Furman, Eric S Winer. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.
Expert opinion on investigational drugs.
2012 Jan; 21(1):15-22. doi:
10.1517/13543784.2012.640318. [PMID: 22112004]